Gen-Probe, Inc.
$1.6M 250 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
ABK Biomedical USA, Inc.
ABK Biomedical USA, Inc. reported $1,644,462.17 across General Payments, Research, and Ownership to 49 physicians and teaching hospitals across 459 transactions.
- $1.6M Above-median payer
- All-tracks total
- 459 Above-median volume
- Transactions
- 49 Below-median reach
- Recipients
- −$6.2K
- General Payments vs PY2023
ABK Biomedical USA, Inc. reported $1,644,462.17 across all CMS Open Payments tracks (General + Research + Ownership) to 49 physicians and teaching hospitals in Program Year 2024 - ranking #496 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $6,556.76, averaging $33.6K per recipient.
How ABK Biomedical USA, Inc.'s $1.6M all-tracks total breaks down
ABK Biomedical USA, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
18/100
Total payments
F
25/100
Transaction volume
F
13/100
Physician reach
F
10/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer abk-biomedical-usa-inc ABK Biomedical USA, Inc.
$1.6M · #496/1,925 · 0.0% industry · PY2024
- TOT $1.6M
- RANK #496
- SHARE 0.0%
- TXN 459
- RCP 49
- CAT 2
- GEN $6.6K
- ΔGEN −$6.2K
- TOP1 33.6%
- PY 2024
Volume peers
Nearest volume peer: Gen-Probe, Inc. ($1.6M)
ABK Biomedical USA, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
ABK Biomedical USA, Inc.'s CMS-reported General Payments decreased by $6.2K (−48.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2023: ABK BIOMEDICAL USA, INC.PY2024: ABK Biomedical USA, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $12,773.59
- PY2024
- $6,556.76
What the Data Shows for ABK Biomedical USA, Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For ABK Biomedical USA, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
The 2-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Food and Beverage" at $4.4K, accounting for 66.4% of this company's General Payments and 47 transactions.
General Payment Breakdown by Type
ABK Biomedical USA, Inc. made 2 types of general payments. "Food and Beverage" is the largest category at $4.4K, 66.4% of General Payments.
How ABK Biomedical USA, Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $4.4K | 47 | 66.4% |
| Consulting Fee | $2.2K | 2 | 33.6% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $3,844.41 (58.6%) of $6,556.76 in this company's General Payments records across 21 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for ABK Biomedical USA, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Matthew Niemeyer
$2,200.00 across 2 reported transactions
- 2
Nadine Abi-Jaoudeh
$530.19 across 5 reported transactions
- 3
Eric Wang
$410.67 across 7 reported transactions
- 4
Jeremy Kim
$386.36 across 6 reported transactions
- 5
Ravi Shridhar
$317.19 across 6 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
ABK Biomedical USA, Inc. ranks #496 of 1,925 by total payments (top 26% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #895 of 1,838 by HHI (top 49% most concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Great Lakes Medical Services, LLC : $5.8K total payments, HHI 1429
- Virtual Incision Corporation : $447.4K total payments, HHI 1423
- Aadi Bioscience, Inc. : $255.4K total payments, HHI 1423
- Empire Medical, Inc : $4.0K total payments, HHI 1422
- Cipla USA Inc. : $2.2M total payments, HHI 1419
- Clinical Laserthermia Systems Americas Inc. : $1.7K total payments, HHI 1414
- ABK Biomedical USA, Inc. (this company) : $6.6K total payments, HHI 1409
- Cadwell Industries, INC : $39.8K total payments, HHI 1407
- Carestream Dental, LLC : $175.9K total payments, HHI 1402
- Daxor Corporation : $270.6K total payments, HHI 1400
- US Retina LLC : $355.0K total payments, HHI 1391
- Biogen, Inc. : $9.2M total payments, HHI 1387
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as ABK Biomedical USA, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about ABK Biomedical USA, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with ABK Biomedical USA, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
KARL STORZ Endoscopy-America
$1.7M 1,585 recipients
Compare payment profiles
Neuropace, Inc.
$1.6M 1,828 recipients
Compare payment profiles
Menarini Silicon Biosystems, Inc.
$1.6M 490 recipients
Compare payment profiles
Terumo Medical Corporation
$1.6M 6,609 recipients
Compare payment profiles
Scpharmaceuticals Inc.
$1.6M 13,366 recipients
Compare payment profiles
Put this to use
ABK Biomedical USA, Inc. ranks #496 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See where ABK Biomedical USA, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just ABK Biomedical USA, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.